SEC Form 4 · accession 0001140361-17-028898
Sienna Biopharmaceuticals, Inc. · SNNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Todd Harris
Officer — Head of Corporate Development · Director
Period of report
Jul 26, 2017
Accepted (ET)
Jul 27, 2017 · 4:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001656328
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $15.00 | Jul 26, 2017 | A | 11,926 | A | — | Jul 26, 2027 | Common Stock | 11,926 | 11,926 | D |
Explanation of responses
- F1Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from July 26, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.